

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Letter]

Lucian Manu

Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA

Correspondence: Lucian Manu, Renaissance School of Medicine at Stony Brook University, 100 Nicolls Road, Putnam Hall, Stony Brook, NY, 11794, USA, Tel +1 631-601-5139, Fax +1 631-350-0286, Email Lucian.Manu@stonybrookmedicine.edu

Dear editor

I have read the article written by Chen et al, “Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis.”¹ The authors provide an important analysis of the treatment of suicidal ideation with ketamine or esketamine, concluding that both may reduce suicidal ideation (SI) within 4–6 hours. This letter is not a rebuttal to the article but, rather, a response to further clarify a few points on the real-world use of ketamine and esketamine.

As the authors noted, esketamine was approved by the US Food and Drug Administration (FDA) as the first therapy for management of depressive symptoms in adults with major depressive disorder with acute SI or behavior² and thus has data establishing its use. The label is specific to the patient population. For example, esketamine nasal spray has the largest clinical randomized controlled trial program and the only registrational program for major depressive disorder with suicidal thoughts or actions (MDSI). The primary endpoint for these studies was reduction in depressive symptoms. Additionally, the esketamine US Risk Evaluation and Mitigation Strategies (REMS) program provides robust real-world safety data that are reported regularly.

The authors cite several safety concerns that have been raised about ketamine. Unlike the clinical trial environment, in which the trial drug quality is consistent and adverse events are captured regularly, real-world use of ketamine is subject to less rigorous oversight. The FDA issued a letter in February 2022 alerting health care professionals that “ketamine is not FDA-approved for the treatment of any psychiatric disorder”, listing the safety concerns. As an approved product, the manufacturing and distribution practices of intranasal esketamine are carefully regulated, and the benefits, risks, and dosing have been established and approved by various regulatory agencies.³ The SPRAVATO REMS program also provides guidance for the monitoring of patients and to ensure that it is dispensed and administered in health care centers, which is an additional safeguard against potential misuse and abuse.

I thank Chen et al for their article, which furthers the scientific literature and understanding of drug efficacy in crisis situations, an area of critical need for patients.

Acknowledgments

Writing and editorial assistance was provided by Janssen and ApotheCom (Yardley, PA) and funded by Janssen Scientific Affairs, LLC.

Disclosure

Lucian Manu has received research funding administered through Stony Brook University from Janssen Pharmaceuticals LLC (developer of esketamine nasal spray) to conduct clinical trials with esketamine, served as a member of the SPRAVATO

Speaker Bureau for Janssen Pharmaceuticals, and served as a member of the Janssen Pharmaceuticals Neuroscience Clinical Advisory Board. The author reports no other conflicts of interest in this communication.

References

1. Chen C-C, Zhou N, Hu N, et al. Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: a systematic review and meta-analysis. *Neuropsychiatr Dis Treat*. 2023;19:587–599. doi:10.2147/NDT.S401032
2. Janssen Pharmaceuticals, Inc. *SPRAVATO® (Esketamine) Nasal Spray, CIII [Prescribing Information]*. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2020.
3. US Food and Drug Administration. *FDA Alerts Health Care Professionals of Potential Risks Associated with Compounded Ketamine Nasal Spray*. US Food and Drug Administration Home Page; 2022. Available from: <https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray>. Accessed June 23, 2023.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Neuropsychiatric Disease and Treatment 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Neuropsychiatric Disease and Treatment editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

<https://doi.org/10.2147/NDT.S428154>